MannKind’s capital raise is not enough, says Jason Kolbert.
Analyst says MannKind’s Afrezza revenues can surpass debt, if investors can be patient for adoption.
Maxim is confident that HMNY’s recent 52% purchase of MoviePass will usher in commercial leverage.
Just before the weekend hits, Maxim’s Nehal Chokshi shares thoughts on his top tech picks: AAPL and NTNX.
Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.
Adamis Stock Can Reach $13 as Symjepi Deal Is Imminent
Analyst Jason Kolbert of Maxim believes that Interpace Diagnostics Group Inc (NASDAQ:IDXG) has quite the upper hand over the leading market ruler Veracyte …
Shares of MannKind Corporation (NASDAQ:MNKD) are up nearly 3% in Friday trading session, as the inhaled insulin drug maker gets a vote …
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) released a grim second quarter print last Thursday, revealing that the management team had lowered guidance across …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday’s trading session, following the news that CEO David Dodd is stepping …